OverviewChartNewsTraderScreen

BNP Paribas Aktienanleihe SNW 26..../  DE000PC1XV12  /

Frankfurt Zert./BNP
21/06/2024  21:40:11 Chg.+0.160 Bid21:59:52 Ask21:59:52 Underlying Strike price Expiration date Option type
95.080EUR +0.17% 95.290
Bid Size: 20,000		 95.390
Ask Size: 20,000		 SANOFI SA INHABER ... 95.00 EUR 26/09/2024 Call
GlobeNewswire 21/06 Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s ...
GlobeNewswire 21/06 Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusi...
GlobeNewswire 20/06 Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
GlobeNewswire 18/06 Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Sm...
GlobeNewswire 11/06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 03/06 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire 31/05 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
GlobeNewswire 31/05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 31/05 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 31/05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 31/05 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire 30/05 Press Release: Sanofi completes acquisition of Inhibrx, Inc.
GlobeNewswire 27/05 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire 23/05 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
GlobeNewswire 21/05 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 20/05 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 20/05 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire 13/05 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 13/05 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire 13/05 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 10/05 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 10/05 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 10/05 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire 09/05 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab